Table 3 Comparison of clinical outcomes according to treatment strategy.

From: Non-randomized comparison between revascularization and deferral for intermediate coronary stenosis with abnormal fractional flow reserve and preserved coronary flow reserve

Per-patient analysis

PCI (N = 231)

Deferred (N = 99)

Unadjusted HR (95% CI)

P value

Adjusted HR* (95% CI)

P value

MACE†

12.7 (20)

14.0 (11)

1.156 (0.553–2.419)

0.700

1.301 (0.611–2.769)

0.495

All-cause death

4.8 (7)

6.0 (5)

1.561 (0.494–4.928)

0.448

2.250 (0.653–7.749)

0.199

Target-vessel MI

1.7 (2)

1.3 (1)

0.985 (0.088–11.03)

0.990

0.654 (0.051–8.389)

0.744

Target-vessel revascularization

7.0 (12)

8.5 (6)

1.056 (0.395–2.823)

0.913

1.089 (0.399–2.975)

0.867

  1. Data expressed as cumulative incidence of clinical outcomes and number of events. Cumulative incidence of clinical outcomes represents Kaplan–Meier estimates during median follow-up of 1286.0 days (Q1-Q3 733.0–1693.0 days). P values for log-rank test in survival analysis.
  2. *Adjusted for age, sex, diabetes mellitus, hypertension, hypercholesterolemia, current smoking, and acute coronary syndrome.
  3. †MACE included all-cause death, target-vessel MI, and target-vessel revascularization.
  4. CI Confidence interval, HR Hazard ratio, MACE Major adverse cardiac events, MI Myocardial infarction, PCI Percutaneous coronary intervention.
Back to article page